内镜随机假手术对照试验:不良事件的系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE和Embase至2017年7月,纳入34篇随机对照试验(1987-2017年)共2492例操作(治疗组1355例/假手术组1137例),评估内镜假手术对照的安全性。假手术组严重不良事件发生率为1.7%(19/1137),治疗组与假手术组发生严重不良事件的比值无显著差异(OR 1.3,95%CI 0.7-2.3),但初始随机至假手术组后交叉接受干预的额外风险显著(RR 1.33,95%CI 1.14-1.56,P<.001)。
要点
- 假手术组严重不良事件发生率为1.7%(19/1137),最常见为需手术或ICU入住(35.3%)。
- 治疗组与假手术组发生严重不良事件的比值无显著差异(OR 1.3,95%CI 0.7-2.3)。
- 初始随机至假手术组后交叉接受干预的额外风险显著(RR 1.33,95%CI 1.14-1.56,P<.001)。
核心结论
- 内镜假手术操作的不良事件频率较高,患者承受相当多的并发症;这些结果对假手术对照试验的使用提出了严重的伦理困境。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE和Embase数据库截至2017年7月,纳入比较内镜治疗与假手术的随机对照试验,共34篇出版物(1987-2017年,100%全文),总计2492例操作(治疗组1355例/假手术组1137例)。
主要发现
- 假手术操作涉及上消化道内镜(31项研究)和内镜逆行胰胆管造影(ERCP)(3项研究)。
- 治疗组操作适应症包括:减重(38.2%)、消化道出血(26.5%)、胃食管反流病(GERD)(20.6%)、Oddi括约肌功能障碍(8.8%)和吞咽困难(6.2%)。
- 假手术组严重不良事件总体百分比为1.7%(19/1137)。
- 假手术组最常见的严重不良事件为需手术或入住重症监护室(35.3%)、ERCP后胰腺炎(23.5%)和穿孔(11.8%)。
- 治疗组与假手术组发生严重不良事件的比值无显著差异(OR 1.3,95%CI 0.7-2.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Sham procedures in endoscopy are used with the intention of controlling for placebo response, potentially allowing more precise evaluation of treatment effect. Nevertheless, this type of study may impose significant risk without potential benefit for those in the sham group. The aim of the current study was to systematically review and analyze the endoscopic literature to assess the safety of sham controls. METHODS: MEDLINE and Embase databases were searched for endoscopic sham procedures for all dates to July 2017. Only randomized controlled trials comparing an endoscopic therapy with a sham were included. Primary outcome was adverse events (AEs) categorized as mild, moderate, or severe. Results were combined using a random-effects model. Heterogeneity was assessed with the I2 statistic, and publication bias was assessed with the Egger test and funnel plots. RESULTS: Data were extracted from 34 publications (1987-2017; 100% full text), with a total of 2492 procedures (1355 treatment/1137 sham). Sham procedures involved upper endoscopy (31 studies) and ERCP (3 studies). Treatment arms included procedures with the following indications: weight loss (38.2%), GI bleeding (26.5%), GERD (20.6%), sphincter of Oddi dysfunction (8.8%), and dysphagia (6.2%). Overall percentage of severe adverse events (SAEs) in the sham group was 1.7% (19/1137). Of these, the most common SAEs in the sham groups were need for surgery/intensive care unit stay (35.3%), post-ERCP pancreatitis (23.5%), and perforation (11.8%). There was no significant difference in the odds of developing an SAE between the treatment group and the sham group (odds ratio, 1.3; 95% confidence interval [CI], 0.7-2.3). The pooled additional risk incurred from being initially randomized to the sham arm and then receiving a cross-over intervention was significant (RR, 1.33; 95% CI, 1.14-1.56; P < .001), compared with patients initially randomized to the study intervention. CONCLUSION: The frequency of AEs in endoscopic sham procedures is substantial, and patients are subjected to considerable morbidity. These results raise a serious ethical dilemma regarding the use of sham-controlled trials.
引用
- Schulman AR, Popov V, Thompson CC, et al. Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events. Gastrointest Endosc. 2017. PMID: 28802556. doi:10.1016/j.gie.2017.07.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。